The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9549930 B1

PDF
Full Text
Expired
Date of Patent:
Jan. 24, 2017

Filed:

Sep. 09, 2015
Applicant:

Quadex Pharmaceuticals, Llc, South Jordan, UT (US);

Inventor:

B. Ron Johnson, Sandy, UT (US);

Assignee:

QUADEX PHARMACEUTICALS, LLC, South Jordan, UT (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/04 (2006.01); A61K 31/70 (2006.01); A61K 31/522 (2006.01); A61K 31/14 (2006.01); A61K 9/00 (2006.01); A61K 31/52 (2006.01); A61K 31/7072 (2006.01); A61K 31/675 (2006.01); A61K 31/245 (2006.01); A61K 45/06 (2006.01); A61K 31/662 (2006.01); A61K 31/7125 (2006.01); A61K 31/7064 (2006.01); A61K 31/7052 (2006.01); A61K 31/706 (2006.01); A61K 31/7076 (2006.01);
U.S. Cl.
CPC ...
A61K 31/522 (2013.01); A61K 9/0014 (2013.01); A61K 31/14 (2013.01); A61K 31/245 (2013.01); A61K 31/52 (2013.01); A61K 31/662 (2013.01); A61K 31/675 (2013.01); A61K 31/7072 (2013.01); A61K 31/7125 (2013.01); A61K 45/06 (2013.01); A61K 31/706 (2013.01); A61K 31/7052 (2013.01); A61K 31/7064 (2013.01); A61K 31/7076 (2013.01);
Abstract

Compositions and methods for treating disordered and/or prodromal stage tissue infected with by a virus in a mammal by co-administering a systemic anti-virus drug and topically administered anti-infective composition. The systemic anti-virus drug is internally administered and disrupts or inhibits virus replication systemically within the mammal. Examples include nucleoside analogs, nucleoside analog precursors, and nucleotide analogs. The topically administered anti-infective composition includes at least one anti-infective agent, such as an organohalide (e.g., benzalkonium chloride), and is formulated to penetrate below the skin surface and allow the anti-infective agent to kill viruses at a treatment site. The topical anti-infective composition enhances efficacy of the systemic anti-virus drug and reduces the time and/or number of dosages otherwise required for the systemic anti-virus drug to treat the viral infection. The topical anti-infective composition can be more beneficial than the systemic anti-virus drug in killing viruses and can reduce or eliminate post-herpetic neuralgia.


Find Patent Forward Citations

Loading…